Types of Inherited Blood Disorders: Which Are Treated With Stem Cell Transplant?

"Inherited blood disorder" covers a range of genetic conditions that affect how the bone marrow makes blood cells, from sickle cell disease to rare bone marrow failure syndromes. Unlike most of the conditions this site covers, several of these disorders already have decades of hematopoietic stem cell transplant (HSCT) experience behind them, and in sickle cell disease specifically, two FDA-approved gene therapies have now reached real patients. This article walks through the major inherited blood disorders by how established — or how early-stage — their stem cell treatment really is, and is honest about the real access barriers that come with even an approved cure.

Sickle Cell Disease: The Most Advanced Story

Sickle cell disease (SCD) is caused by a single gene mutation that makes red blood cells rigid and sickle-shaped, leading to pain crises, organ damage, and reduced life expectancy. It affects an estimated 100,000 people in the United States, occurring in roughly 1 in 365 Black or African American births, and the disease disproportionately affects Black and Hispanic communities. Allogeneic HSCT — a bone marrow or cord blood transplant from a matched donor — has been used as a curative option for decades, mainly in children with a well-matched sibling donor, and can eliminate symptoms entirely when successful.

The genuinely significant recent development is gene therapy, which sidesteps the need for a donor by modifying a patient's own stem cells. In December 2023, the FDA approved Casgevy (exagamglogene autotemcel), the first CRISPR gene-editing therapy authorized in the U.S. for any condition, alongside Lyfgenia (lovotibeglogene autotemcel), a second gene therapy using a different lentiviral-vector approach — both for sickle cell disease in patients 12 and older. This is real, durable progress worth taking seriously. It is also worth being honest about the gap between approval and access: by the end of 2025, roughly 64 patients had received Casgevy infusions and reporting indicates over 100 have received Lyfgenia, modest numbers given an eligible population in the tens of thousands. Both therapies require a demanding conditioning regimen using the chemotherapy drug busulfan, which carries a real risk of infertility, and industry analysts and patient advocates have pointed to gaps in physician awareness, time away from work, and manufacturing capacity as ongoing access barriers even where insurance coverage exists.

Beta-Thalassemia: A Parallel, Earlier Path

Beta-thalassemia, a related inherited disorder in which the body produces too little functional hemoglobin, follows a similar but somewhat more established pattern: allogeneic HSCT has long been used as a curative option for transfusion-dependent patients with a matched donor, and Casgevy's FDA approval also covers transfusion-dependent beta-thalassemia (approved January 2024), alongside an earlier-approved gene-addition therapy (betibeglogene autotemcel, brand name Zynteglo) cleared by the FDA in August 2022. As with sickle cell disease, the treatment exists and works for some patients; broad, affordable access remains the harder, still-unresolved problem.

Fanconi Anemia and Aplastic Anemia: Transplant as Standard of Care, No Gene Therapy Yet

Fanconi anemia is a rare inherited DNA-repair disorder that leads to progressive bone marrow failure and a sharply elevated cancer risk; allogeneic HSCT is the established standard treatment for the bone marrow failure component, typically using a matched sibling or unrelated donor, though patients remain at elevated risk for certain cancers even after a successful transplant. Severe aplastic anemia, which can be inherited or acquired, similarly has allogeneic HSCT as a well-established curative option for younger patients with a matched donor, with immunosuppressive therapy as the main alternative when no donor is available. Neither condition currently has an FDA-approved gene therapy; transplant from a donor remains the primary stem-cell-based option for both.

What's Still Early-Stage

Beyond these better-established conditions, inherited platelet disorders, certain inherited immune deficiencies, and rarer marrow failure syndromes (such as Diamond-Blackfan anemia and Shwachman-Diamond syndrome) are also treated with allogeneic HSCT in select cases, generally with less published long-term outcome data than sickle cell disease or thalassemia. Gene therapy research is actively underway for several of these conditions, but none currently has FDA approval specific to that use.

Bottom Line

Inherited blood disorders are genuinely a bright spot in stem cell medicine: allogeneic transplant has offered a real cure for sickle cell disease, beta-thalassemia, Fanconi anemia, and aplastic anemia for years, and CRISPR-based gene therapy has now turned "cure without a donor" into an approved reality for sickle cell disease and beta-thalassemia specifically. The honest caveat is that approval is not the same as access — demanding conditioning regimens, high costs, and gaps in physician awareness mean most eligible patients have not yet been treated, even for therapies the FDA has cleared. Anyone exploring these options should work with a hematologist at a transplant center experienced in the specific disorder involved.